Alzheimer's Disease Biomarker Panel

About Neurocode

Neurocode is a private, commercial-stage diagnostics company founded in 2018, specializing in advanced testing for neurological and neuroimmunological disorders. Its core offerings include a proprietary plasma p-Tau217 assay for Alzheimer's disease and an exclusive, licensed live cell-based assay for AChR antibodies in myasthenia gravis. Operating a CAP/CLIA-certified lab, the company generates revenue by providing these high-sensitivity tests to clinicians, researchers, and clinical trial sponsors. Neurocode positions itself as a leader in niche neurology diagnostics through technological exclusivity and a focused service model.

Therapeutic Areas